Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep - Excellent Overall Survival in Non-Small Cell Lung Cancer (ASX:IMM)

Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with...read more

Immutep announces publication of ESMO 2023 abstracts (ASX:IMM)

New updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Saturday, October 21st, at 9:05 CEST Immute...read more

Immutep announces acceptance of abstract for SITC 2023 (ASX:IMM)

SYDNEY, AUSTRALIA – 3 October 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing...read more

Immutep - Commercial Scale Manufacturing of Efti for Clinical Trials (ASX:IMM)

SYDNEY, AUSTRALIA – September 21, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company develop...read more

Immutep - 2023 AGM & Key Dates (ASX:IMM)

SYDNEY, AUSTRALIA – 8 September 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) advises that in accordance with ASX Listing Rule 3.13.1, that it intends to hold its 2023 Annual General M...read more

Immutep to Participate in September Investor Conferences (ASX:IMM)

SYDNEY, AUSTRALIA – 6 September 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical stage biotechnology company developing nov...read more

Immutep - Appendix 4E & 2023 Full Year Statutory Accounts (ASX:IMM)

To view the Appendix 4E & 2023 Full Year Statutory Accounts, download the attached PDF.

Immutep receives positive scientific advice from EMA (ASX:IMM)

SYDNEY, AUSTRALIA – 1 August 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel ...read more

Immutep - Efti clinical data to be presented at ESMO Congress 2023 (ASX:IMM)

-- Mini Oral presentation will include data from TACTI-002 Phase II trial evaluating chemotherapy-free IO combination of efti plus KEYTRUDA® (pembrolizumab) -- Two additional posters on investi...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

Late-stage & registrational trial progress: -- TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational trial in 1st line non-small cell lung cancer (1L NSCLC) ...read more

Immutep - 1st Patient Dosed in Phase 2 Soft Tissue Sarcoma Trial (ASX:IMM)

SYDNEY, AUSTRALIA – 28 July 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel L...read more

Application for quotation of securities - IMM (ASX:IMM)

To view the application, download the attached PDF.

Immutep - US patent granted for Efti with PD-1 pathway inhibitor (ASX:IMM)

SYDNEY, AUSTRALIA – 27 June 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disea...read more

Immutep - US patent granted for Efti with PD-1 pathway inhibitor (ASX:IMM)

Immutep completes underwritten retail entitlement offer (ASX:IMM)

On Wednesday, 31 May 2023, Immutep Limited ACN 009 237 889 (ASX: IMM) (Immutep or the Company) announced a fully underwritten placement to institutional investors (Placement) and 1 for 7.6 pro rata ...read more

Viewing: 61 - 75 of 200 Previous | Next